Data Packages. 2.6.1. With respect to each Research Target, within [***] after the completion of the Development activities set forth in the Research Plan for such Research Target (or, if earlier, [***] prior to the end of the Option Period), Morphic shall deliver to AbbVie the Data Package for such Research Target and shall provide AbbVie with electronic access to all data generated in connection with the Development activities under the Research Plan with respect to such Research Target.
Data Packages. On a Program Slot-by-Program Slot basis, within [***] days after [***] (or such other period of time mutually agreed by the Parties), Caribou shall deliver to AbbVie the complete Data Package with respect to the applicable Program Slot. [***]
Data Packages. Merus shall: (i) at the direction of the JRC, provide to Incyte the Data Package for Program 1 and Program 2 and their corresponding Bi-Specific Constructs, and (ii) on a Program-by-Program basis, use Commercially Reasonable Efforts to provide to Incyte within [**] (or such other longer period as may be set forth in the applicable Research Plan) following designation of each Target Pair pursuant to Sections 4.4 or 4.5, the Data Package for such Target Pair, including the corresponding General Monoclonal Antibodies, Selected Monoclonal Antibodies and the Bi-Specific Construct(s) that specifically bind to such Target Pair that are the subject of such Program, and which have been the subject of research activities under the applicable Research Plan.
Data Packages. Merus shall: (i) at the direction of the JRC, provide to Incyte the Data Package for Program 1 and Program 2 and their corresponding Bi-Specific Constructs, and (ii) on a Program-by-Program basis, use Commercially Reasonable Efforts to provide to Incyte within [*] (or such other longer period as may be set forth in the applicable Research Plan) following designation of each Target Pair pursuant to Sections 4.4 or 4.5, the Data Package for such Target Pair, including the corresponding General Monoclonal Antibodies, [*] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. Confidential Treatment Requested Under 17 C.F.R.§§ 200.80(b)(4) and 240-24b-2 Selected Monoclonal Antibodies and the Bi-Specific Construct(s) that specifically bind to such Target Pair that are the subject of such Program, and which have been the subject of research activities under the applicable Research Plan.
Data Packages. (i) As promptly as practicable following completion of each Designated Clinical Trial or other study (including clinical and non-clinical) with respect to a Product conducted by or on behalf of Company during the Company Development Period and, in any event, no later than one hundred twenty (120) days following database lock of such Designated Clinical Trial or other study, Company shall prepare and deliver to Amgen the Data Package for such Designated Clinical Trial or other study. Moreover, during the Company Development Period, Company shall provide to Amgen, when available following database lock of each Designated Clinical Trial, top-line data summaries, summaries of draft data generated prior to completion of the applicable Data Package and raw data from each Designated Clinical Trial. To the extent that Company performs an interim data review, or otherwise reviews or receives material data prior to completion of a Designated Clinical Trial or other study, Company shall promptly make available to Amgen such data and/or the results of such review, as applicable.
Data Packages. With respect to each Data Package, the Party providing such Data Package to the other Party hereby represents and warrants to such other Party, as of the Delivery Date for such Data Package, that to the providing Party’s Knowledge, such Data Package is true, complete and correct.
Data Packages. For each Research Program with respect to a Xxxxxxx Antigen, the Research Plan shall describe the contents of the DC Data Package and IND Data Package for such Research Program.
Data Packages. In consideration for providing Data Packages to Hyseq under the Collaboration, Hyseq will pay to Aurora a non-creditable, non-refundable payment of [***] within [***] after delivery of each Data Package to Hyseq. Notwithstanding the foregoing, CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24b-2 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED. Hyseq will pay to Aurora a minimum of [***] during the Collaboration Period under this Section 5.1(d).
Data Packages. In consideration for providing Data Packages to Hyseq under the Collaboration, Hyseq will pay to Aurora a non-creditable, non-refundable payment of [***] within [***] after delivery of each Data Package to Hyseq. Notwithstanding the foregoing, Hyseq will pay to Aurora a minimum of [***] during the Collaboration Period under this Section 5.1(d).
Data Packages. Within [***] of the Effective Date and prior to the provision of any Data Package for a 23andMe Pre-Existing Program to GSK, 23andMe shall notify GSK in writing of the identity of each Target that is the subject of a 23andMe Pre-Existing Program so that GSK may decide whether it wishes to receive the corresponding Data Package. 23andMe shall include in such notification a list of no more than [***] of such 23andMe Pre-Existing Programs that it desires be subject to accelerated review for exercise of GSK’s Option (such Programs, the “Accelerated Option Review Programs”). The Target information set forth in the notice shall be deemed to be Level 4 Data and shall be provided to GSK and accessed in accordance with the principles applicable to Xxxxx 0 Data and set forth in the Data Access Plan. Following receipt of such information, GSK shall decide whether it wishes to receive the Data Package for the respective 23andMe Pre-Existing Program and provide notice to 23andMe of its decision; provided that if GSK provides such notice more than [***] after receipt of the Target information (i.e., the full list of Targets), then the applicable Option Period shall be reduced on a day-for-day basis. If GSK notifies 23andMe that it does not wish to receive the Data Package for any applicable 23andMe Pre-Existing Program, GSK’s Option with respect to the applicable 23andMe Pre-Existing Program shall be deemed to have been terminated as of such notification date. Prior to GSK providing notice to 23andMe of its decision to receive a Data Package for a 23andMe Pre-Existing Program, GSK shall ensure that access to the identity of the Target that is the subject of such 23andMe Pre-Existing Program is restricted to no more than [***] GSK employees, each of whom is involved in the decision-making process with respect to such 23andMe Pre-Existing Program (and which employees may be different for each Target). For each 23andMe Pre-Existing Program that GSK notifies that it elects to receive a Data Package, 23andMe shall provide GSK with a report and data package corresponding to the activities conducted by 23andMe and its Affiliates for such 23andMe Pre-Existing Program prior to the delivery of such report and data package, which report and data package shall contain the data and information set forth on Schedule 5.1(c) based on its stage of development (each, a “Data Package”) in order for GSK to decide whether to exercise the Option to such 23andMe Pre-Existing Program. Each Dat...
